The scavenging of superoxide radicals promotes apoptosis induced by a novel cell-permeable fusion protein, sTRAIL:FeSOD, in tumor necrosis factor-related apoptosis-inducing ligand-resistant leukemia cells

BMC Biology

Volumn 9, Issue , 2011, Pages

  Tang, Hongyun ^a   Qin, Yong ^a   Li, Jianyong ^a   Gong, Xingguo ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; HYDROGEN PEROXIDE; PROTEIN KINASE B; SUPEROXIDE; SUPEROXIDE DISMUTASE; TNFRSF10A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CELL STRAIN K 562; DRUG EFFECT; HUMAN; METABOLISM;

APOPTOSIS; HL-60 CELLS; HUMANS; HYDROGEN PEROXIDE; K562 CELLS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT FUSION PROTEINS; SUPEROXIDE DISMUTASE; SUPEROXIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952694839     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/1741-7007-9-18     Document Type: Article

References (44)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682. 10.1016/1074-7613(95)90057-8, 8777713.
2. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27:6207-6215. 10.1038/onc.2008.298, 18931688.
3. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155-162. 10.1172/JCI6926, 408479, 10411544.
4. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157-163. 10.1038/5517, 9930862.
5. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000, 6:564-567. 10.1038/75045, 10802713.
6. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000, 60:553-559.
7. Itoh M, Noutomi T, Toyota H, Mizuguchi J. Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Oral Oncol 2003, 39:269-276. 10.1016/S1368-8375(02)00114-8, 12618199.
8. Dida F, Li Y, Iwao A, Deguchi T, Azuma E, Komada Y. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. Exp Hematol 2008, 36:1343-1353. 10.1016/j.exphem.2008.04.011, 18599181.
9. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008, 6:1861-1871. 10.1158/1541-7786.MCR-08-0313, 19074831.
10. Fas SC, Baumann S, Zhu JY, Giaisi M, Treiber MK, Mahlknecht U, Krammer PH, Li-Weber M. Wogonin sensitizes resistant malignant cells to TNFα- and TRAIL-induced apoptosis. Blood 2006, 108:3700-3706. 10.1182/blood-2006-03-011973, 16931628.
11. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007, 6:66. 10.1186/1476-4598-6-66, 2134932, 17953743.
12. Meurette O, Fontaine A, Rebillard A, Le Moigne G, Lamy T, Lagadic-Gossmann D, Dimanche-Boitrel MT. Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann N Y Acad Sci 2006, 1090:209-216. 10.1196/annals.1378.023, 17384264.
13. Koschny R, Walczak H, Ganten TM. The promise of TRAIL: potential and risks of a novel anticancer therapy. J Mol Med 2007, 85:923-935. 10.1007/s00109-007-0194-1, 17437073.
14. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF, Helfrich W. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 2005, 280:10025-10033. 10.1074/jbc.M413673200, 15644326.
15. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967. 10.1016/0092-8674(93)90719-7, 8402885.
16. Kang J, Chen J, Zhang D, Da W, Ou Y. Synergistic killing of human leukemia cells by antioxidants and trichostatin A. Cancer Chemother Pharmacol 2004, 54:537-545. 10.1007/s00280-004-0845-7, 15248029.
17. Behrend L, Mohr A, Dick T, Zwacka RM. Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol 2005, 25:7758-7769. 10.1128/MCB.25.17.7758-7769.2005, 1190300, 16107721.
18. Jubeh TT, Antler S, Haupt S, Barenholz Y, Rubinstein A. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Mol Pharm 2005, 2:2-11. 10.1021/mp0499095, 15804172.
19. Lu M, Gong X, Lu Y, Guo J, Wang C, Pan Y. Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells: inhibition cell proliferation through the Akt/p27kip1 pathway. J Biol Chem 2006, 281:13620-13627. 10.1074/jbc.M600523200, 16551617.
20. Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 2001, 276:6893-6896. 10.1074/jbc.C000569200, 11145953.
21. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 2008, 7:1156-1163. 10.1158/1535-7163.MCT-07-2183, 2715176, 18483303.
22. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 2007, 67:1430-1435. 10.1158/0008-5472.CAN-06-1224, 17308080.
23. Martin D, Salinas M, Fujita N, Tsuruo T, Cuadrado A. Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B. J Biol Chem 2002, 277:42943-42952. 10.1074/jbc.M201070200, 12213802.
24. Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem 2007, 282:12831-12841. 10.1074/jbc.M700438200, 17327223.
25. Li D, Randhawa VK, Patel N, Hayashi M, Klip A. Hyperosmolarity reduces GLUT4 endocytosis and increases its exocytosis from a VAMP2-independent pool in L6 muscle cells. J Biol Chem 2001, 276:22883-22891. 10.1074/jbc.M010143200, 11297538.
26. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998, 10:559-563. 10.1016/S0952-7915(98)80224-0, 9794836.
27. Lum JJ, Schnepple DJ, Badley AD. Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions. AIDS 2005, 19:1125-1133. 10.1097/01.aids.0000176212.16205.23, 15990565.
28. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal 1999, 11:1-14. 10.1016/S0898-6568(98)00037-0, 10206339.
29. Matysiak M, Jurewicz A, Jaskolski D, Selmaj K. TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain 2002, 125:2469-2480. 10.1093/brain/awf254, 12390973.
30. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995, 270:296-299. 10.1126/science.270.5234.296, 7569979.
31. Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, Holbeck SL, Peter ME. Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci USA 2003, 100:11445-11450. 10.1073/pnas.2034995100, 208777, 14504390.
32. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573. 10.1016/j.ccr.2005.05.014, 15950905.
33. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008, 8:782-798. 10.1038/nrc2465, 18813321.
34. Perez-Cruz I, Carcamo JM, Golde DW. Vitamin C inhibits FAS-induced apoptosis in monocytes and U937 cells. Blood 2003, 102:336-343. 10.1182/blood-2002-11-3559, 12623840.
35. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 2003, 81:664-673. 10.1007/s00109-003-0476-1, 12928788.
36. Perez-Cruz I, Carcamo JM, Golde DW. Caspase-8 dependent TRAIL-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 2007, 12:225-234. 10.1007/s10495-006-0475-0, 17031493.
37. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schon MP, Henkler F, Gollnick H, Walczak H, Leverkus M. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 2008, 27:3211-3220. 10.1038/sj.onc.1210985, 18084329.
38. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994, 83:1179-1187.
39. Cheng J, Hylander BL, Baer MR, Chen X, Repasky EA. Multiple mechanisms underlie resistance of leukemia cells to Apo2 ligand/TRAIL. Mol Cancer Ther 2006, 5:1844-1853. 10.1158/1535-7163.MCT-06-0050, 16891471.
40. Mohr A, Büneker C, Gough RP, Zwacka RM. MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release. Oncogene 2008, 27:763-774. 10.1038/sj.onc.1210673, 17653087.
41. Hietakangas V, Poukkula M, Heiskanen KM, Karvinen JT, Sistonen L, Eriksson JE. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol 2003, 23:1278-1291. 10.1128/MCB.23.4.1278-1291.2003, 141136, 12556488.
42. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993, 5:625-630. 10.1093/intimm/5.6.625, 7688561.
43. Harper N, MacFarlane M. Recombinant TRAIL and TRAIL receptor analysis. Methods Enzymol 2008, 446:293-313. full_text, 18603130.
44. Andrieu N, Salvayre R, Jaffrézou JP, Levade T. Low temperatures and hypertonicity do not block cytokine-induced stimulation of the sphingomyelin pathway but inhibit nuclear factor-κB activation. J Biol Chem 1995, 270:24518-24524. 10.1074/jbc.270.41.24518, 7592669.